Clinical and laboratory characteristics of monoclonal TCRαβ+/CD4+ LGL lymphocytosis according to the type of TCR-Vβ family expressed (Vβ13.1 versus non-Vβ13.1) compared with monoclonal TCRαβ+/CD8+ LGL lymphocytosis
| Characteristic . | Monoclonal TCRαβ+/CD4+ LGL lymphocytosis . | Monoclonal TCRαβ+/CD8+ LGL lymphocytosis . | P . | ||
|---|---|---|---|---|---|
| TCR-Vβ13.1 . | Non-TCR-Vβ13.1 . | Total cases . | |||
| No. of patients | 15 | 21 | 36 | 24 | |
| Mean age ± 1 SD, y (range) | 64 ± 8 (52-80) | 61 ± 13 (36-81) | 63 ± 12 (36-81) | 56 ± 15 (31-79) | NS |
| % male/% female | 25/75 | 61/39 | 47/53 | 37/63 | NS |
| Reason for consulting, %; | |||||
| Routine blood analysis | 100 | 83 | 90 | 83 | NS |
| Skin lesions | 0 | 11 | 7 | 0 | NS |
| Abdominal distension | 0 | 6 | 3 | 0 | NS |
| Fever | 0 | 0 | 0 | 4 | NS |
| General symptoms | 0 | 0 | 0 | 13 | NS |
| Physical examination, %; | |||||
| Adenomegalies | 11 | 6 | 7 | 0 | NS |
| Hepatomegaly | 0 | 0 | 0 | 4 | NS |
| Splenomegaly | 0 | 6 | 3 | 4 | NS |
| Skin lesions | 0 | 11 | 7 | 0 | NS |
| Associated neoplasias, % | 25 | 22 | 23 | 26 | NS |
| Associated autoimmune diseases, % | 18 | 0 | 13 | 33 | .05 |
| Laboratory parameters, %; | |||||
| Leukocytosis, WBC count more than 10 × 109/L | 64 | 61 | 63 | 25 | .01 |
| Lymphocytosis, lymphocyte count more than 5 × 109/L | 70 | 67 | 68 | 42 | .09 |
| Neutropenia, neutrophil count less than 1.5 × 109/L | 14 | 0 | 3 | 61 | < .001 |
| Anemia, hemoglobin level less than 10 g/dL | 0 | 0 | 0 | 29 | .003 |
| Thrombocytopenia, platelet count less than 100 × 109/L | 10 | 0 | 3 | 8 | NS |
| Increased lactic dehydrogenase level, more than 460 U/L | 10 | 0 | 3 | 22 | NS |
| Increased β2-microglobulin level, more than 2 mg/dL | 0 | 7 | 3 | 63 | .001 |
| Cases requiring treatment because of lymphocytosis or the associated autoimmune disease, % | 0 | 0 | 0 | 37 | .001 |
| Outcome: stable disease, % | 100 | 100 | 100 | 87 | NS |
| Total deaths, % | 10 | 18 | 15 | 8 | NS |
| Deaths related to the TCRαβ+ LGL lymphocytosis, % | 0 | 0 | 0 | 4 | NS |
| Mean follow-up ± 1 SD, mo (range) | 68 ± 48 (13-136) | 74 ± 56 (10-233) | 72 ± 53 (10-233) | 44 ± 40 (1-152) | .03 |
| Characteristic . | Monoclonal TCRαβ+/CD4+ LGL lymphocytosis . | Monoclonal TCRαβ+/CD8+ LGL lymphocytosis . | P . | ||
|---|---|---|---|---|---|
| TCR-Vβ13.1 . | Non-TCR-Vβ13.1 . | Total cases . | |||
| No. of patients | 15 | 21 | 36 | 24 | |
| Mean age ± 1 SD, y (range) | 64 ± 8 (52-80) | 61 ± 13 (36-81) | 63 ± 12 (36-81) | 56 ± 15 (31-79) | NS |
| % male/% female | 25/75 | 61/39 | 47/53 | 37/63 | NS |
| Reason for consulting, %; | |||||
| Routine blood analysis | 100 | 83 | 90 | 83 | NS |
| Skin lesions | 0 | 11 | 7 | 0 | NS |
| Abdominal distension | 0 | 6 | 3 | 0 | NS |
| Fever | 0 | 0 | 0 | 4 | NS |
| General symptoms | 0 | 0 | 0 | 13 | NS |
| Physical examination, %; | |||||
| Adenomegalies | 11 | 6 | 7 | 0 | NS |
| Hepatomegaly | 0 | 0 | 0 | 4 | NS |
| Splenomegaly | 0 | 6 | 3 | 4 | NS |
| Skin lesions | 0 | 11 | 7 | 0 | NS |
| Associated neoplasias, % | 25 | 22 | 23 | 26 | NS |
| Associated autoimmune diseases, % | 18 | 0 | 13 | 33 | .05 |
| Laboratory parameters, %; | |||||
| Leukocytosis, WBC count more than 10 × 109/L | 64 | 61 | 63 | 25 | .01 |
| Lymphocytosis, lymphocyte count more than 5 × 109/L | 70 | 67 | 68 | 42 | .09 |
| Neutropenia, neutrophil count less than 1.5 × 109/L | 14 | 0 | 3 | 61 | < .001 |
| Anemia, hemoglobin level less than 10 g/dL | 0 | 0 | 0 | 29 | .003 |
| Thrombocytopenia, platelet count less than 100 × 109/L | 10 | 0 | 3 | 8 | NS |
| Increased lactic dehydrogenase level, more than 460 U/L | 10 | 0 | 3 | 22 | NS |
| Increased β2-microglobulin level, more than 2 mg/dL | 0 | 7 | 3 | 63 | .001 |
| Cases requiring treatment because of lymphocytosis or the associated autoimmune disease, % | 0 | 0 | 0 | 37 | .001 |
| Outcome: stable disease, % | 100 | 100 | 100 | 87 | NS |
| Total deaths, % | 10 | 18 | 15 | 8 | NS |
| Deaths related to the TCRαβ+ LGL lymphocytosis, % | 0 | 0 | 0 | 4 | NS |
| Mean follow-up ± 1 SD, mo (range) | 68 ± 48 (13-136) | 74 ± 56 (10-233) | 72 ± 53 (10-233) | 44 ± 40 (1-152) | .03 |
P value corresponds to comparisons between monoclonal TCRαβ+/CD4+ LGL and TCRαβ+/CD8+ LGL lymphocytosis; NS indicates no statistically significant differences: P > .1. No statistically significant differences (P > .05) were found between TCR-Vβ13.1 and non-TCR-Vβ13.1 clonal CD4+ LGL lymphocytosis. A detailed description of the clinical characteristics of patients with monoclonal TCRαβ+/CD4+ LGL lymphocytosis is provided by Lima et al.18